From Gene to Medications - The Science of CYP2C19 Testing

Inside the report

1. 01 The sciencewhat CYP2C19 does and why it matters for antiplatelet therapy
2. 02 Clinical useCYP2C19 testing in stroke and TIA care
3. 03 Testing in practicewho orders it, where it runs and how fast results come back
4. 04 Point-of-caresystems that bring the test closer to the patient
5. 05 Barriersawareness, reimbursement and workflow
6. 06 Outlookwhere pharmacogenomic testing goes next

What this report tells you

Pharmacogenomics is moving from research into routine care, and CYP2C19 testing is one of its clearest use cases. This report explains the science behind the test, its role in antiplatelet therapy for stroke and TIA patients, and how it is being used in practice.

It covers who orders the test and where it runs, the shift towards point-of-care systems, the barriers that slow adoption, and where the field is heading.

The full report is available on request. Leave your details below and our team will email it to you.